R&D Investing in biologics excellence In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs.
News Vogenx surpasses expectations with $81M IPO With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
